Despite more than three decades of intensive effort, no effective pharmacological inhibitors
of the RAS oncoproteins have reached the clinic, prompting the widely held perception that …

There is now considerable and increasing evidence for a causal role for aberrant activity of
the Ras superfamily of small GTPases in human cancers. These GTPases function as GDP …

KRAS GTPases are activated in one-third of cancers, and KRAS (G12C) is one of the most
common activating alterations in lung adenocarcinoma,. KRAS (G12C) inhibitors, are in …

Protein farnesylation and geranylgeranylation, together referred to as prenylation, are lipid
post-translational modifications that are required for the transforming activity of many …

Although the roots of Ras sprouted from the rich history of retrovirus research, it was the
discovery of mutationally activated RAS genes in human cancer in 1982 that stimulated an …

Temporally and spatially controlled activation of the Aurora A kinase (AURKA) regulates
centrosome maturation, entry into mitosis, formation and function of the bipolar spindle, and …

The RAS oncogenes (HRAS, NRAS and KRAS) comprise the most frequently mutated class
of oncogenes in human cancers (33%), thus stimulating intensive effort in developing anti …

Mitochondria exist as dynamic interconnected networks that are maintained through a
balance of fusion and fission. Equal distribution of mitochondria to daughter cells during …

KRAS mutated tumours represent a large fraction of human cancers, but the vast majority
remains refractory to current clinical therapies. Thus, a deeper understanding of the …

The centrosomal Aurora-A kinase (AURKA) regulates mitotic progression, and
overexpression and hyperactivation of AURKA commonly promotes genomic instability in …